Inventor · disambiguated record
Ted M. Dawson
Also filed as: DAWSON TED · DAWSON TED M
20 granted patents·15 pending applications·573 citations·filing 1992–2024
95Inventor score
Files withUNIV JOHNS HOPKINS17GUILFORD PHARM INC5DAWSON TED M3UNIV JOHNS HOPKINS MED2UNIV SOUTHERN METHODIST2
Top patents by PatentIndex Score
35 records- 0192US5798355AInhibitors of rotamase enzyme activityGUILFORD PHARM INC·Filed 1995·Granted Aug 25, 1998·110 cites·34 claims
- 0292US5587384AInhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicityUNIV JOHNS HOPKINS·Filed 1994·Granted Dec 24, 1996·109 cites·20 claims
- 0390USRE36397EInhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicityUNIV JOHNS HOPKINS·Filed 1998·Granted Nov 16, 1999·87 cites·4 claims
- 0488US6358975B1Method of using selective parp inhibitors to prevent or treat neurotoxicityUNIV JOHNS HOPKINS·Filed 2000·Granted Mar 19, 2002·43 cites·7 claims
- 0581US6500843B2Inhibitors of rotamase enzyme activityGUILFORD PHARM INC·Filed 1999·Granted Dec 31, 2002·31 cites·42 claims
- 0679US5843960AInhibitors of rotamase enzyme activityGUILFORD PHARM INC·Filed 1997·Granted Dec 1, 1998·29 cites·6 claims
- 0778US8603994B2Transcriptional repression leading to Parkinson's diseaseDAWSON TED M·Filed 2011·Granted Dec 10, 2013·3 cites·9 claims
- 0878US5266594AInhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicityDAWSON VALINA L·Filed 1992·Granted Nov 30, 1993·65 cites·18 claims
- 0972US2024398824A1Inhibition Of Rip Kinases For Treating Neurodegenerative DisordersUNIV JOHNS HOPKINS·Filed 2024·Application pending·0 cites
- 1067US9309208B2Methods of making and using thioxothiazolidine and rhodanine derivatives as HIV-1 and JSP-1 inhibitorsUNIV SOUTHERN METHODIST·Filed 2013·Granted Apr 12, 2016·1 cites·2 claims
- 1167US5898029ADirect influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factorsUNIV JOHNS HOPKINS·Filed 1994·Granted Apr 27, 1999·30 cites·29 claims
- 1267US2025161413A1Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereofDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 1366US12276657B2Detection of PAR in the CSF of patients with Parkinson's diseaseUNIV JOHNS HOPKINS·Filed 2022·Granted Apr 15, 2025·0 cites·10 claims
- 1466US12233109B2Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditionsUNIV JOHNS HOPKINS·Filed 2021·Granted Feb 25, 2025·0 cites·32 claims
- 1564US5846981AInhibitors of rotamase enzyme activityGUILFORD PHARM INC·Filed 1997·Granted Dec 8, 1998·24 cites·10 claims
- 1661US8921042B2Transcriptional repression leading to Parkinson's diseaseVALTED LLC·Filed 2013·Granted Dec 30, 2014·0 cites·3 claims
- 1760US2022249597A1Mif inhibitors and methods of use thereofUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 1859US9274128B2Transcriptional repression leading to parkinson's diseaseVALTED LLC·Filed 2014·Granted Mar 1, 2016·0 cites·3 claims
- 1959US6080753AStimulating nerve growth with immunophilinsUNIV JOHNS HOPKINS MED·Filed 1997·Granted Jun 27, 2000·19 cites·16 claims
- 2059US2023012209A1Methods of preventing or treating parkinson's disease by the farnesylation of parisUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 2157US6022878AInhibitors of rotamase enzyme activityGUILFORD PHARM INC·Filed 1998·Granted Feb 8, 2000·8 cites·42 claims
- 2256US11123405B2Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditionsUNIV JOHNS HOPKINS·Filed 2016·Granted Sep 21, 2021·0 cites·33 claims
- 2351US2021148898A1Detection of par in the csf of patients with parkinson's diseaseUNIV JOHNS HOPKINS·Filed 2018·Application pending·0 cites
- 2451US2003114365A1Inhibitors of rotamase enzyme activityGPI NIL HOLDING INC·Filed 2002·Application pending·0 cites
- 2550US6362160B1Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseasesUNIV JOHNS HOPKINS MED·Filed 1993·Granted Mar 26, 2002·14 cites·18 claims
- 2649US2021322427A1Inhibition of rip kinases for treating neurodegenerative disordersUNIV JOHNS HOPKINS·Filed 2019·Application pending·0 cites
- 2747US2022372014A1Neuroprotective compounds and methods of use thereofUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 2844US2019224274A1Mif inhibitors and methods of use thereofUNIV JOHNS HOPKINS·Filed 2017·Application pending·0 cites
- 2943US2022291240A1Biomarkers for neurodegenerative disordersUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 3042US2019117586A1Methods of preventing or treating parkinson's disease by the farnesylation of parisUNIV JOHNS HOPKINS·Filed 2018·Application pending·0 cites
- 3141US2016250194A1Methods of Making and Using Thioxothiazolidine and Rhodanine Derivatives as HIV-1 and JSP-1 InhibitorsUNIV SOUTHERN METHODIST·Filed 2016·Application pending·0 cites
- 3240US2019194324A1THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTORUNIV JOHNS HOPKINS·Filed 2017·Application pending·0 cites
- 3338US2015018301A1LRRK-2-Mediated Neuronal ToxicityLEE BYOUNG DAE·Filed 2010·Application pending·0 cites
- 3435US9623039B2Treatment and prevention of pathological conditions using iduna related techniques and compositionsDAWSON TED M·Filed 2011·Granted Apr 18, 2017·0 cites·1 claims
- 3530US2012122765A1Compounds and related methods for manipulating parp-1-dependent cell deathDAWSON TED M·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →